Derniers essais


EudraCT Number: 2022-000439-22 Sponsor Protocol Number: 67953964MDD3001_VENTURA-1 Start Date: 2023-01-25
Sponsor Name: Janssen-Cilag International NV
Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
Medical condition: Major Depressive Disorder (MDD)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004873 10025453 Major depressive disorder NOS LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Ongoing) HU (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005947-58 Sponsor Protocol Number: M1095-PSA-201 Start Date: 2023-01-25
Sponsor Name: MoonLake Immunotherapeutics AG
Full Title: Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients with Active Psoriatic Arthritis
Medical condition: Active Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
21.0 100000004859 10037160 Psoriatic arthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Ongoing) ES (Ongoing) HU (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001484-27 Sponsor Protocol Number: NL67672.091.18 Start Date: 2023-01-24
Sponsor Name: radboudumc
Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2
Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002924-11 Sponsor Protocol Number: LOLAbiome Start Date: 2023-01-09
Sponsor Name: CBmed GmbH
Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis
Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2)
Disease: Version SOC Term Classification Code Term Level
20.0 100000004871 10024667 Liver cirrhosis LLT
20.0 100000004852 10014630 Encephalopathy hepatic LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003079-41 Sponsor Protocol Number: BOLD-100-001 Start Date: 2023-01-06
Sponsor Name: Bold Therapeutics, Inc. (Bold)
Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours
Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10052362 Metastatic colorectal cancer LLT
21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
20.1 100000004864 10017770 Gastric carcinoma LLT
21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-004931-10 Sponsor Protocol Number: R3918-PNH-2050 Start Date: 2023-01-04
Sponsor Name: Regeneron Pharmaceuticals, Inc.
Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: GR (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001387-10 Sponsor Protocol Number: 220301 Start Date: 2022-12-29
Sponsor Name: TECNIMEDE, Sociedade Técnico-Medicinal, S.A.
Full Title: A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumoni...
Medical condition: Coronavirus disease 2019 (COVID-19 pneumonia)
Disease: Version SOC Term Classification Code Term Level
25.1 100000004862 10066740 Acute respiratory tract infection LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001685-35 Sponsor Protocol Number: ADT-2022-003 Start Date: 2022-12-27
Sponsor Name: Adeptio Pharmaceuticals Limited
Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia.
Medical condition: Tardive dyskinesia
Disease: Version SOC Term Classification Code Term Level
21.1 10029205 - Nervous system disorders 10043118 Tardive dyskinesia PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-000380-46 Sponsor Protocol Number: 75276617ALE1003 Start Date: 2022-12-27
Sponsor Name: Janssen-Cilag International NV
Full Title: A Phase I/Ib Study of JNJ-75276617 in Combination with Conventional Chemotherapy for Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleo...
Medical condition: Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
21.0 100000004864 10060354 Acute myeloblastic leukaemia LLT
21.0 100000004864 10000833 Acute leukaemia of unspecified cell type LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001539-10 Sponsor Protocol Number: UX007-CL302 Start Date: 2022-12-27
Sponsor Name: Ultragenyx Pharmaceutical Inc.
Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient...
Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10077951 Fatty acid oxidation disorder PT
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: ES (Ongoing) CZ (Ongoing)
Trial results: (No results available)